Quinazoline‐chalcone hybrids as HDAC/EGFR dual inhibitors: Design, synthesis, mechanistic, and in‐silico studies of potential anticancer activity against multiple myeloma
Archiv der Pharmazie · 2024-05 · 357 (5)
DOI: 10.1002/ardp.202300626 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 31.01.2024. Verfasst von Mostafa A Mansour und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Chemistry Department, Faculty of Pharmacy, Nahda University in Beni-Suef (NUB), Beni-Suef, Egypt. Hauptthemen laut MEDLINE: Drug Design, Quinazolines, Chalcone, Histone Deacetylase Inhibitors. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 111 Literaturangaben. Gefördert von: None.
Abstract (Originalsprache)
Two new series of quinazoline‐chalcone hybrids were designed, synthesized as histone deacetylase (HDAC)/epidermal growth factor receptor (EGFR) dual inhibitors, and screened in vitro against the NCI 60 human cancer cell line panel. The most potent derivative, compound 5e bearing a 3,4,5‐trimethoxyphenyl chalcone moiety, showed the most effective growth inhibition value against the panel of NCI 60 human cancer cell lines. Thus, it was selected for further investigation for NCI 5 log doses. Interestingly, this trimethoxy‐substituted analog inhibited the proliferation of Roswell Park Memorial Institute (RPMI)‐8226 cells by 96%, at 10 µM with IC 50 = 9.09 ± 0.34 µM and selectivity index = 7.19 against normal blood cells. To confirm the selectivity of this compound, it was evaluated against a panel of tyrosine kinase enzymes. Mechanistically, it successfully and selectively inhibited HDAC6, HDAC8, and EGFR with IC 50 = 0.41 ± 0.015, 0.61 ± 0.027, and 0.09 ± 0.004 µM, respectively. Furthermore, the selected derivative induced apoptosis via the mitochondrial apoptotic pathway by raising the Bax/Bcl‐2 ratio and activating caspases 3, 7, and 9. Also, the flow cytometry analysis of RPMI‐8226 cells showed that the trimethoxy‐substituted analog produced cell cycle arrest in the G1 and S phases at 55.82%. Finally, an in silico study was performed to explore the binding interaction of the most active compound within the zinc‐containing binding site of HDAC6 and HDAC8.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, Nahda University in Beni-Suef (NUB), Beni-Suef, Egypt.
- Medicinal Chemistry Department, Faculty of Pharmacy, Minia University, Minia, Egypt.
- Medicinal Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut, Egypt.
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, Badr University in Assiut (BUA), Assiut, Egypt.
Förderung
- None
Zitieren
APA
Mansour, M. A., AboulMagd, A. M., Abbas, S. H., Abdel-Aziz, M., & Abdel-Rahman, H. M. (2024). Quinazoline‐chalcone hybrids as HDAC/EGFR dual inhibitors: Design, synthesis, mechanistic, and in‐silico studies of potential anticancer activity against multiple myeloma. Archiv der Pharmazie, 357(5). https://doi.org/10.1002/ardp.202300626
Vancouver
Mansour MA, AboulMagd AM, Abbas SH, Abdel-Aziz M, Abdel-Rahman HM. Quinazoline‐chalcone hybrids as HDAC/EGFR dual inhibitors: Design, synthesis, mechanistic, and in‐silico studies of potential anticancer activity against multiple myeloma. Archiv der Pharmazie. 2024;357(5). doi:10.1002/ardp.202300626
BibTeX
@article{Mansour2024,
author = {Mansour, Mostafa A and AboulMagd, Asmaa M and Abbas, Samar H and Abdel-Aziz, Mohamed and Abdel-Rahman, Hamdy M},
title = {Quinazoline‐chalcone hybrids as HDAC/EGFR dual inhibitors: Design, synthesis, mechanistic, and in‐silico studies of potential anticancer activity against multiple myeloma},
journal = {Archiv der Pharmazie},
year = {2024},
volume = {357},
number = {5},
doi = {10.1002/ardp.202300626}
}
EUVIMED